TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03506425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triheptanoin
Description: Triheptanoin is a medium chain triglyceride (MCT) that can improve mitochondrial function and energy production and therefore has potential for slowing ALS progression. Indeed, triheptanoin slowed motor neuron loss and delayed the onset of weakness in a mutant SOD1 model of ALS. The Triheptanoin we will use is a colorless to light yellow oil. The target triheptanoin dose for this study is 1g/kg/d. This target dose was selected because it was safe and tolerable and altered brain MR spectroscopy in patients with Huntington's Disease.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triheptanoin
Description: Triheptanoin is a medium chain triglyceride (MCT) that can improve mitochondrial function and energy production and therefore has potential for slowing ALS progression. Indeed, triheptanoin slowed motor neuron loss and delayed the onset of weakness in a mutant SOD1 model of ALS. The Triheptanoin we will use is a colorless to light yellow oil. The target triheptanoin dose for this study is 1g/kg/d. This target dose was selected because it was safe and tolerable and altered brain MR spectroscopy in patients with Huntington's Disease.
Study: NCT04525859

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Safety
Description: See previous Safety group description

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Expansion Cohort
Description: See previous Expansion Cohort
Study: NCT01461369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac
Description: 35 mg bid Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac
Description: 35 mg tid Capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules
Study: NCT00963599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: montelukast/loratadine
Description: montelukast 10 mg/loratadine 10 mg tablet taken once daily at bed time for 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: montelukast
Description: montelukast 10 mg tablet taken once daily at bed time for 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: loratadine
Description: loratadine 10 mg tablet taken once daily at bed time for 2 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: placebo
Description: placebo tablet taken once daily at bed time for 2 weeks
Study: NCT04475068

Intervention type: PROCEDURE
Intervention: Lateral Position (left and right lateral decubitus)
Description: Prior to initiating the protocol, patients will be sedated deeply with sedatives and opioids and paralyzed. Patients will be evaluated in 5 positions sequentially: 1) Supine 2) Left lateral 3) Supine 4) Right lateral 5) Supine. The side with the least ventilation evaluated by EIT will define which side will start the sequence. Each step will last 30 minutes. Aeration measured by Electric Impedance Tomography (EIT) and lung ultrasound, distribution of the lung ventilation and perfusion measured by EIT, ventilator and hemodynamic parameters, esophageal pressure, and blood gas analysis will be recorded at the end of each step. Continuous monitoring of blood pressure, heart rate and saturation of arterial blood (SpO2) will be carried out during all steps of the protocol to assess the tolerance to the procedure.
Study: NCT02065973

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: R-enantiomer of 1,2-dioleoyl-3-trimethylammonium-propane chloride + Peptides from HPV-16 E6 and E7

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: R-enantiomer of 1,2-dioleoyl-3-trimethylammonium-propane chloride + Peptides from HPV-16 E6 and E7
Study: NCT01523691

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Repeated sleep restriction and recovery
Description: Repeated cycles of sleep restriction and sleep recovery

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control sleep
Description: Regular amounts of sleep across study protocol
Study: NCT02065973

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: R-enantiomer of 1,2-dioleoyl-3-trimethylammonium-propane chloride + Peptides from HPV-16 E6 and E7
Study: NCT04442178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYT107
Description: IM administration at 10μg/kg twice a week for three weeks and up to 7 administrations according to Hospital length of stay
Study: NCT05266690

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Roquette Glucidex 2
Description: Roquette Glucidex 2: Maltodextrins with high degree of polymerization

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Roquette Glucidex 2
Description: Roquette Glucidex 2: Maltodextrins with high degree of polymerization

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Roquette Glucidex 2
Description: Roquette Glucidex 2: Maltodextrins with high degree of polymerization

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Roquette Glucidex 2
Description: Roquette Glucidex 2: Maltodextrins with high degree of polymerization
Study: NCT04442178

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IM administration at 10μg/kg twice a week for three weeks and up to 7 administrations according to Hospital length of stay
Study: NCT05135143

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Antioxidant formula
Description: Administration of antioxidant formula 3 times a day and once daily.
Study: NCT05266690

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pharmacosmos Dextran 10
Description: Pharmacosmos Dextran 10: Dextran with high degree of polymerization

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pharmacosmos Dextran 10
Description: Pharmacosmos Dextran 10: Dextran with high degree of polymerization

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pharmacosmos Dextran 10
Description: Pharmacosmos Dextran 10: Dextran with high degree of polymerization

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pharmacosmos Dextran 10
Description: Pharmacosmos Dextran 10: Dextran with high degree of polymerization

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Roquette Glucidex 40
Description: Roquette Glucidex 40: Glucose syrup

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Roquette Glucidex 40
Description: Roquette Glucidex 40: Glucose syrup
Study: NCT05135143

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Antioxidant formula
Description: Administration of antioxidant formula 3 times a day and once daily.
Study: NCT01874730

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Combined epidural-general anesthesia (CEGA)
Description: Combined epidural-general anesthesia (CEGA) will be used intraoperatively and patient-controlled epidural analgesia (PCEA) will be used postoperatively in a multimodal analgesic regimen.
Study: NCT00333320

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: Percutaneous coronary interventions were performed following international guidelines. No additional intervention was performed in the control group.
Study: NCT03816020

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nicotinamide Riboside
Description: Nicotinamide Riboside capsules 250mg x 2 BID

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules BID
Study: NCT01582490

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Instillation - EXPAREL
Description: Intravenous (IV) morphine sulfate, hydromorphone, or oral oxycodone with acetaminophen (5/325 mg) will be permitted following surgery, as needed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infiltration - EXPAREL
Description: IV morphine sulfate, hydromorphone, or oral oxycodone with acetaminophen (5/325 mg) will be permitted following surgery, as needed.
Study: NCT04750499

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adipose tissue injection associated with endorectal advancement flap.
Description: Injection of adipose tissue will be associated with endorectal advancement flap technique. In blind fistulas and special cases, in which the flap is not indicated, alternative techniques will be used. In all cases, autologous, micro-fragmented and minimally manipulated adipose tissue, obtained with a standardized procedure, previously validated and authorized, will be injected. This procedure uses the Lipogems ® device (Lipogems International SpA, Milan, Italy), with which a well-characterized adipose tissue is obtained with the maximum safety guarantees.
Study: NCT03048214

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Infraclavicular nerve block
Description: Infraclavicular nerve block is a relatively safe and straightforward brachial plexus nerve block that can be used to provide intraoperative regional anaesthesia for upper limb surgeries from the elbow to fingers.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: General anaesthesia
Description: Usual practice for upper limb surgeries.
Study: NCT00961675

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FST201 (dexamethasone 0.1% with povidone-iodine 1%)
Description: 4 gtt BID (twice a day)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprodex (Ciprofloxacin 0.3%; dexamethasone 0.1% )
Description: 4 gtt BID (twice a day)
Study: NCT02872714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemigatinib
Description: Pemigatinib once a day by mouth for 2 consecutive weeks and 1 week off therapy.
Study: NCT05266690

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Roquette Glucidex 40
Description: Roquette Glucidex 40: Glucose syrup

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Roquette Glucidex 40
Description: Roquette Glucidex 40: Glucose syrup
Study: NCT02872714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemigatinib
Description: Pemigatinib once a day by mouth for 2 consecutive weeks and 1 week off therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemigatinib
Description: Pemigatinib once a day by mouth continuously.
Study: NCT03822091

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terlipressin
Description: Patients with Type 1 HRS will be given Terlipressin at the dose of 2mg/24 hrs as infusion. After 48 hours of initial monitoring, patients who do not respond to the initial dose of Terlipressin, and randomised into group A and B. Group A patients will receive further higher doses of Terlipressin. The dose of Terlipressin will be increased by 1mg after 24 hrs if:~* the creatinine values decrease by \<12.5%~* MAP increase of \<10 mmHg~* urine output of \<200 ml in 4 hours.~Maximum terlipressin dose will be given upto 12 mg/day.Albumin will be administered in both arms according to standard protocol at the following dose :~1. 1st day - Albumin at 1 gram/kg - a maximum dose of 100grams can be given.~2. A dose of 20gram/day to 60gram/day in the following days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terlipressin and Noradrenaline
Description: Patients with Type 1 HRS will be given Terlipressin at the dose of 2mg/24 hrs as infusion. After 48 hours of initial monitoring, patients who do not respond to the initial dose of Terlipressin, will be randomised into group A and B. Group B patients will be treated with~Terlipressin(2mg/24hr infusion- fixed dose) and Noradrenaline, which would be given as a continuous infusion at a starting dose of 0.5 mg/hr. The dose od noradrenaline will be increased every 24 hours in steps of 0.5 mg/hr, the maximum dose being 3 mg/hr IF:~* the creatinine values decrease by \<12.5%~* MAP increase of \<10 mmHg~* urine output of \<200 ml in 4 hours.
Study: NCT02055924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib and immunochemotherapies
Description: Combination of immunochemotherapies (R-DHAP or R-DHAOx) and ibrutinib
Study: NCT04131660

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AVAPS-AE mode during NIV
Description: NIV will be setup in AVAPS-AE mode, with a Trilogy ventilation device (Respironics, Murrysville, PA). The range of positive expiratory pressure will be set between 4 and 14 cmH2O. The range of inspiratory pressure support will be set between 14 and 24 cmH2. The target tidal volume will be set to achieve 8 to 10 mL/kg of ideal body weight (Size (m) \* Size (m) \* 23).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: S/T mode during NIV
Description: NIV will be setup in ST mode, with a Trilogy ventilation device (Respironics, Murrysville, PA).~The physician will decide the level of positive expiratory pressure and of pressure support.
Study: NCT04059835

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OptiBra study
Description: compare two different bra after breast cancer surgery

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: OptiBra study
Description: compare two different bra after breast cancer surgery
Study: NCT02861807

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brain stimulation with mindfulness-based relapse prevention
Description: Participants will participate in weekly or twice weekly group mindfulness based relapse prevention (MBRP) + transcranial direct current stimulation (tDCS) intervention sessions for up to eight weeks. All participants will receive 8 two hour sessions of MBRP + tDCS, regardless of the group schedule. Subjects will receive 30 minutes of either active or sham tDCS stimulation, depending on their group assignment. After tDCS, sessions will include discussions of mindfulness as a means of coping with craving, cognitions, and emotions, role play exercises, and mindfulness practice.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Brain stimulation with mindfulness-based relapse prevention
Description: Participants will participate in weekly or twice weekly group mindfulness based relapse prevention (MBRP) + transcranial direct current stimulation (tDCS) intervention sessions for up to eight weeks. All participants will receive 8 two hour sessions of MBRP + tDCS, regardless of the group schedule. Subjects will receive 30 minutes of either active or sham tDCS stimulation, depending on their group assignment. After tDCS, sessions will include discussions of mindfulness as a means of coping with craving, cognitions, and emotions, role play exercises, and mindfulness practice.
Study: NCT01686373

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Activa Dose II Real tDCS
Description: 20 minutes of 1 milliamp active tDCS per treatment day (15 total sessions)

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Activa Dose II Sham tDCS
Description: 20 minutes of sham stimulation per treatment day (15 total sessions)
Study: NCT02731430

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intrathecal morphine
Description: received 0.3mg morphine (0.3ml) added to 1.2ml of bupivacaine 0.5% (total volume 1.5ml), intrathecally, immediately before induction of general anesthesia.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: intrathecal saline
Description: received 0.3ml saline added to 1.2mlof bupivacaine 0.5% (total volume 1.5ml), intrathecally, immediately before induction of general anesthesia.
Study: NCT04361773

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Photobiomodulation
Description: Treatment with a device with 144 light emitting diodes (LEDs) at wavelengths of 420, 660 and 850nm, 3J per point for 10 minutes.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Photobiomodulation
Description: Simulation of the LED application, with a device with external characteristics identical to that of the PBM group, for the same period of time.
Study: NCT04151186

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TM4SF1- and EpCAM-positive chimeric antigen receptor T-cell therapy
Description: Specification: 30 mL-100 mL, cell density of about (1-10) x10\^6 cells/ml in each bag, number of T-cells about (1-10) x10\^8 cells.) 300 ml for each infusion.~Storage: The prepared CAR T-cells are cryopreserved in a preserving medium . This product is manufactured under the current good manufacture practices (cGMP) conditions, with restrictions on chemical components, free from animal- or human-derived components and confirming to the United States Pharmacopeia (USP)\<71\> and \<85\> regulations.~Preservation: The frozen CAR T-cells are preserved in the liquid nitrogen transfer tank.~Usage: The frozen CAR T-cells are preserved at low temperature and transferred to the bedside. The cells are thawed by 36 degrees centigrade to 38 degrees centigrade. water bath. The frozen cells are gently massaged until complete thawing. Then they are transfused back to the patients intravenously. The transfusion will be finished within 5-10 min.
Study: NCT01874730

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Volulyte® (6% HES 130/0.4 in balanced solution)
Description: For the SOC Group: Intraoperative fluid management includes Volulyte® (6% HES 130/0.4 in balanced solution) as the only colloid solution to be used, the daily dosage of Volulyte® is restricted to 50 ml/kg.~For the ERS Group:~GDFT regimen will be utilized using Volulyte® (6% HES 130/0.4 in balanced solution) during surgery. The daily dosage of Volulyte® is restricted to 50 ml/kg.

Intervention type: DRUG
Group type: OTHER
Intervention: Volulyte® (6% HES 130/0.4 in balanced solution)
Description: For the SOC Group: Intraoperative fluid management includes Volulyte® (6% HES 130/0.4 in balanced solution) as the only colloid solution to be used, the daily dosage of Volulyte® is restricted to 50 ml/kg.~For the ERS Group:~GDFT regimen will be utilized using Volulyte® (6% HES 130/0.4 in balanced solution) during surgery. The daily dosage of Volulyte® is restricted to 50 ml/kg.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient-Controlled Epidural Analgesia (PCEA)
Description: For the ERS Group, patient-controlled epidural analgesia (PCEA) will be used postoperatively in a multimodal analgesic regimen.
Study: NCT00736060

Intervention type: OTHER
Intervention: Observational
Description: Summary of clinical and laboratory data
Study: NCT02631642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMPL-689
Description: selective PI3Kδ inhibitor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HMPL-689 placebo
Description: placebo of HMPL-689
Study: NCT01559077

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ALN-TTR02
Description: Dose levels between 0.01 and 0.5 mg/kg by intravenous (IV) infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sterile Normal Saline (0.9% NaCl)
Description: Calculated volume to match active comparator
Study: NCT02418884

Intervention type: DRUG
Group type: OTHER
Intervention: rosuvastatin
Description: CAD patients with diabetes who confirmed CAC will receive rosuvastatin (20mg/d) therapy for 24 months.
Study: NCT02593695

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation
Description: Deep brain stimulation of bilateral nucleus accumbens

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fluoxetine
Description: Fluoxetine is one of selective serotonin reuptake inhibitors(SSRIs).
Study: NCT03786588

Intervention type: OTHER
Intervention: Observation
Description: The patients with the negative results of HPV infection, and assigned to different group according to the CPP manifestation.
Study: NCT04162743

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trazodone
Description: take trazodone 100mg before polysomnography

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: take placebo oral tablet before polysomnography
Study: NCT02946476

Intervention type: OTHER
Intervention: prognostic impact of non cardiac comorbidities

Intervention type: OTHER
Intervention: prognostic impact of non cardiac comorbidities
Study: NCT03915132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Description: Nimotuzumab 200mg/m2 IV on d1 of a week before radiotherapy , and 100mg/m2 IV on d1 weekly for 7 cycles

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: VMAT
Description: Intensity-modulated radiotherapy was given to the patients with regimen of 69.96 Gy-73.92 Gy to the gross target volume of nasopharynx,69.96 Gy to the gross target volume of positive nodes, 60.06 Gy the high risk clinical target volume, 50.96 Gy to the low risk clinical target volume.
Study: NCT01375062

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: analyse and proliferate the cells
Description: 1. Obtention of excess tissue from testicular biopsies and maintained in 4ºC until procedures.~2. Digestion of the biopsies through controlled enzymes~3. Replication of the cells~4. Selection undifferentiated cells~5. Expansion of the purification cells population~6. Characterization of the cell population~7. Assessment of pluripotent and germinal cell potential.~8. Possible maturation of the cells.
Study: NCT00226499

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Priorix-tetra™
Description: 2 doses administered subcutaneously, one at Day 0 and the other at Day 42 to subjects in MMRV Group

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Priorix™
Description: 2 doses administered subcutaneously, one at Day 0 and the other at Day 42 to subjects in MMR Group and one dose administered subcutaneously at Day 0 to subjects in OKAH Group

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Priorix™
Description: 2 doses administered subcutaneously, one at Day 0 and the other at Day 42 to subjects in MMR Group and one dose administered subcutaneously at Day 0 to subjects in OKAH Group

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Varilrix™
Description: 1 dose administered subcutaneously at Day 42 to subjects in OKAH Group
Study: NCT00620945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenoxybenzamine
Description: Use of Phenoxybenzamine:~Loading dose given at the time of going on CPB:~* For patients with obstructing lesions on systemic side:~  * 0.25 mg/kg dose in the bypass circuit~ * None intravenous~* For patients without obstructing left sided lesions:~  * 0.5 mg/kg in the bypass circuit~ * 0.5 mg/kg I.V. at cannulation~Maintenance dose given in the post-operative period:~* 0.3 mg/kg I.V. every 8 hours till oral intake is started or for first 48 hours~* 0.3 mg/kg P.O. every 8 hours for next 24 hours~* 0.15 mg/kg P.O. every 8 hours for next 24 hours and then stop~* Hold PBZ if the patient is on norepinephrine infusion or the mean arterial pressure is lower than that allowed for the age group
Study: NCT02503540

Intervention type: DRUG
Group type: OTHER
Intervention: Aflibercept
Description: Intravitreal aflibercept will be given q4 wks for 6 treatments and then q 8 weeks through month 12.
Study: NCT04056260

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ICG-NIR guided surgery
Description: ICG 0.5mg/ml x 0.5ml x 4 sites injection through intra-operative endoscopy